• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
Latest trends in two-dose vaccination against measles among children in the US

Latest trends in two-dose vaccination against measles among children in the US

by Truveta Research | Apr 3, 2025 | Research, Research Insights

The vaccination rate by age six fluctuated between 2018 and 2021; however, rates have decreased since 2021. The rate in 2021 was 81.9% compared to 80.4% in 2024. This means for every 70 children, roughly one more child received two measles vaccines in 2021 compared to...
Latest US first-time measles vaccination trends for children under 24 months

Latest US first-time measles vaccination trends for children under 24 months

by Truveta Research | Apr 3, 2025 | Research, Research Insights

Measles vaccination rates for children under 24 months in 2024 remain lower than in 2020.   In 2024, the average yearly measles vaccination rate for children by 13 months was 58.9% and 68.5% for children by 15 months.   Vaccination patterns for children living in both...
Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

by Truveta staff | Apr 1, 2025 | Research

GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through February 2025 

Real-time monitoring of respiratory virus-associated hospitalizations: Trends through February 2025 

by Truveta staff | Mar 31, 2025 | Research

The overall rate of respiratory virus-associated hospitalizations decreased in February, although influenza continues to be the leading cause of respiratory virus-associated hospitalizations (3.5% of all hospitalizations). Among children aged 0–4 years,...
GLP-1 RA prescription trends: January 2018 – December 2024

GLP-1 RA prescription trends: January 2018 – December 2024

by Truveta staff | Mar 7, 2025 | Research

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
Real-world insights on heart failure recovery: A missed opportunity in guideline-directed therapy

Real-world insights on heart failure recovery: A missed opportunity in guideline-directed therapy

by Truveta staff | Feb 26, 2025 | Research

Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
« Older Entries
Next Entries »

Share this


Recent posts

  • Completing the evidence picture with linked EHR and closed claims data
  • Truveta recognized on national and Seattle LinkedIn Top Startup 2025 lists
  • AI and imaging open new avenues for studying body composition at scale

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.